New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...